Joe Kai
Has grant
Head of Division, Primary Care
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Oxybutynin or venlafaxine for hot flushes in women who cannot or choose not to use hormone replacement therapy: randomised trial and economic evaluation (the BLUSH trial)
Open Date: 2022-09-01
Close Date: 2026-09-01
Grant: Open
Lipid-modifying therapy in children with familial hypercholesterolemia
Open Date: 2022-09-01
Close Date: 2027-09-01
Grant: Close
Reducing Premature Coronary Artery Disease in Malaysia by early identification of Familial Hypercholesterolaemia
Open Date: 2019-12-01
Close Date: 2021-12-01
Grant: Close
RCT of clinical and cost effectiveness of Alpha-Stim cranial electrotherapy stimulation in treatment seeking patients with moderate severity or persistent mild depressive episodes in primary care.
Open Date: 2019-10-01
Close Date: 2022-03-01
Grant: Close
Coordinated care of rare diseases (CONCORD): mixed methods study
Open Date: 2018-01-01
Close Date: 2021-01-01
Articles (12)
Year:
2026
Background Cascade testing the relatives of people with familial hypercholesterolaemia is an efficient approach to identifying familial hypercholesterolaemia. The cascade-testing protocol starts with identifying an index patient with familial hypercholesterolaemia, followed by one of three approaches to contact other relatives: indirect approach, whereby index patients contact their relatives; direct approach, whereby the specialist contacts the relatives; or a combination of both direct and indirect approaches. However, it is unclear which protocol may be most effective. Objectives The objectives were to determine the yield of cases from different cascade-testing protocols, treatment patterns, and short- and long-term outcomes for people with familial hypercholesterolaemia; to evaluate the cost-effectiveness of alternative protocols for familial hypercholesterolaemia cascade testing; and to qualitatively assess the acceptability of different cascade-testing protocols to individuals and families with familial hypercholesterolaemia, and to health-care providers. Design and methods This study comprised systematic reviews and analysis of three data sets: PASS (PASS Software, Rijswijk, the Netherlands) hospital familial hypercholesterolaemia databases, the Clinical Practice Research Datalink (CPRD)–Hospital Episode Statistics (HES) linked primary–secondary care data set, and a specialist familial hypercholesterolaemia register. Cost-effectiveness modelling, incorporating preceding analyses, was undertaken. Acceptability was examined in interviews with patients, relatives and health-care professionals. Result Systematic review of protocols: based on data from 4 of the 24 studies, the combined approach led to a slightly higher yield of relatives tested [40%, 95% confidence interval (CI) 37% to 42%] than the direct (33%, 95% CI 28% to 39%) or indirect approaches alone (34%, 95% CI 30% to 37%). The PASS databases identified that those contacted directly were more likely to complete cascade testing ( p < 0.01); the CPRD–HES data set indicated that 70% did not achieve target treatment levels, and demonstrated increased cardiovascular disease risk among these individuals, compared with controls (hazard ratio 9.14, 95% CI 8.55 to 9.76). The specialist familial hypercholesterolaemia register confirmed excessive cardiovascular morbidity (standardised morbidity ratio 7.17, 95% CI 6.79 to 7.56). Cost-effectiveness modelling found a net health gain from diagnosis of –0.27 to 2.51 quality-adjusted life-years at the willingness-to-pay threshold of £15,000 per quality-adjusted life-year gained. The cost-effective protocols cascaded from genetically confirmed index cases by contacting first- and second-degree relatives simultaneously and directly. Interviews found a service-led direct-contact approach was more reliable, but combining direct and indirect approaches, guided by index patients and family relationships, may be more acceptable. Limitations Systematic reviews were not used in the economic analysis, as relevant studies were lacking or of poor quality. As only a proportion of those with primary care-coded familial hypercholesterolaemia are likely to actually have familial hypercholesterolaemia, CPRD analyses are likely to underestimate the true effect. The cost-effectiveness analysis required assumptions related to the long-term cardiovascular disease risk, the effect of treatment on cholesterol and the generalisability of estimates from the data sets. Interview recruitment was limited to white English-speaking participants. <jats:sec id=
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Collaborators (11)
Ralph Akyea
Senior Research Fellow
University of Nottingham
William Evans
University of Nottingham
Jane Daniels
Professor of Clinical Trials
University of Nottingham
Manpreet Bains
University of Nottingham
Stephen Morris
RAND Professor of Health Services Research, University of Cambridge
University of Cambridge
Edward Cox
Health Economist
University of Nottingham
Asam Latif
University of Nottingham
Pedro Rafael Saramago Goncalves
Senior Research Fellow
University of York
Barbara Iyen
Clinical Associate Professor
University of Nottingham
Christian D Mallen
Associate Director of Research and Innovation
Keele University
Miruna David
University Hospitals Birmingham NHS Foundation Trust
Make your next move.
Prepare your application
Review drafts before you send them.